Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-Based Induction in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Outcomes from a Single Institution

Marc Schwartz, Christine M. McMahon, Maria L Amaya, Matthew Witkowski, Daniel A. Pollyea, Jonathan A Gutman, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2023-188118

Published: 2023

Journal Articles

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

Haley M. Simpson, Brett M Stevens, Craig T. Jordan, M. Eric Kohler

Blood (2023) 142 (Supplement 1): 2064.

https://doi.org/10.1182/blood-2023-182123

Published: 2023

Journal Articles

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Hunter Tolison, Cassandra Duarte, Glen Peterson, Grace N Bosma, Diana Abbott, Gemlyn George, Daniel Pollyea, Craig T. Jordan, Maria L Amaya

Blood (2023) 142 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2023-179669

Published: 2023

Journal Articles

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Maria L Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A Gutman, Connor Sohalski, Jennifer Tobin, Austin E Gillen, Anagha Inguva Sheth, Brett M Stevens, Clayton Smith, Craig T. Jordan, Daniel A. Pollyea

Blood (2023) 142 (Supplement 1): 2914.

https://doi.org/10.1182/blood-2023-182966

Published: 2023

Journal Articles

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Blood (2023) 142 (Supplement 1): 588.

https://doi.org/10.1182/blood-2023-188285

Published: 2023

Journal Articles

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Marc Schwartz, Jonathan A Gutman, Christine M. McMahon, Maria L Amaya, Daniel A. Pollyea, Matthew Witkowski, Mohd Minhajuddin, Clayton Smith, Craig T. Jordan

Blood (2023) 142 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2023-188298

Published: 2023

Journal Articles

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Blood (2022) 140 (Supplement 1): 3275–3276.

https://doi.org/10.1182/blood-2022-157802

Published: 2022

Journal Articles

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Mohd Minhajuddin, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Nicholas Miltgen, Ji Yuan, Amy Treece, Jonathan A. Gutman, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6274–6275.

https://doi.org/10.1182/blood-2022-167856

Published: 2022

Journal Articles

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Anagha Inguva, Krysta L. Engel, Hunter Tolison, Mark J Althoff, Shanshan Pei, Maria L. Amaya, Anna Krug, Mohammad Minhajuddin, Courtney L Jones, Austin E. Gillen, Monica Ransom, Sarah Staggs, Daniel A. Pollyea, Clayton Smith, Brett M. Stevens, Craig T. Jordan

Blood (2022) 140 (Supplement 1): 5922–5923.

https://doi.org/10.1182/blood-2022-167787

Published: 2022

Journal Articles

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Christine M. McMahon, Kellen Gil, Maria L. Amaya, Jonathan A. Gutman, Alexander Hayden, Marc Schwartz, Grace Bosma, Diana Abbott, Brett M. Stevens, Clayton Smith, Craig T Jordan, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 6185–6186.

https://doi.org/10.1182/blood-2022-170168

Published: 2022

Journal Articles

Targeting Microenvironmental Signals in Myeloid Malignancies

Benjamin Rodems, Sonali Sharma, Takashi Ito, Craig T Jordan, Michael W. Becker, Laura M. Calvi, John M. Ashton, Jeevisha Bajaj

Blood (2022) 140 (Supplement 1): 2897.

https://doi.org/10.1182/blood-2022-163601

Published: 2022

Journal Articles

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Alexander Hayden, Grace Bosma, Jonathan A. Gutman, Maria L. Amaya, Diana Abbott, Clayton Smith, Brett M. Stevens, Craig T. Jordan, Daniel A. Pollyea, Christine M. McMahon

Blood (2022) 140 (Supplement 1): 9163–9164.

https://doi.org/10.1182/blood-2022-171064

Published: 2022

Journal Articles

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

Mohd Minhajuddin, Amanda C. Winters, Marc Schwartz, Daniel A. Pollyea, Craig T Jordan

Blood (2022) 140 (Supplement 1): 5986–5987.

https://doi.org/10.1182/blood-2022-169167

Published: 2022

Journal Articles

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Maria L. Amaya, Anagha Inguva, Shanshan Pei, Courtney Jones, Anna Krug, Haobin Ye, Mohammad Minhajuddin, Amanda Winters, Steffanie L. Furtek, Fabia Gamboni, Brett Stevens, Angelo D’Alessandro, Daniel A. Pollyea, Philip Reigan, Craig T. Jordan

Blood (2022) 139 (4): 584–596.

https://doi.org/10.1182/blood.2021013201

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

Amanda C. Winters, Grace Bosma, Diana Abbott, Mohd Minhajuddin, Craig T Jordan, Daniel A. Pollyea, Jonathan A. Gutman

Blood (2021) 138 (Supplement 1): 3957.

https://doi.org/10.1182/blood-2021-154392

Published: 2021

Journal Articles

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Tzu-Chieh Ho, Hiroki Kawano, Mark W. LaMere, Naxin Guo, Yu-Chiao Chiu, Jian Wang, Craig T. Jordan, Nikolay V. Dokholyan, Laura M. Calvi, Rakesh Kumar Singh, Michael W. Becker

Blood (2021) 138 (Supplement 1): 1175.

https://doi.org/10.1182/blood-2021-149903

Published: 2021

Journal Articles

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

Brett M. Stevens, Amanda C. Winters, Mohammad Minhajuddin, Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Clayton Smith, Deng Wang, Connor Adkins, Olivia Ondracek, Craig T. Jordan, Daniel A. Pollyea

Blood (2021) 138 (Supplement 1): 2612.

https://doi.org/10.1182/blood-2021-150824

Published: 2021

Journal Articles

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Mohd Minhajuddin, Haobin Ye, Amanda C. Winters, Shanshan Pei, Nabilah Khan, Brett M. Stevens, Biniam Adane, Maria L. Amaya, Anagha Inguva, Anna Krug, Maura Gasparetto, Daniel W. Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 630.

https://doi.org/10.1182/blood-2021-151400

Published: 2021

Journal Articles

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Brett M. Stevens, Krysta L. Engel, Austin E. Gillen, Rachel Culp-Hill, Angelo Dalessandro, Scott Alper, Daniel A. Pollyea, Craig T. Jordan

Blood (2021) 138 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2021-150749

Published: 2021

Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-138832

Published: 2020

NARROW

Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-Based Induction in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Outcomes from a Single Institution

A Novel CD64 CAR-T Therapy for the Treatment of Monocytic Acute Myeloid Leukemia

A Qualitative Study Comparing the Patient and Provider Experience in an Academic Blood Disorder Center

Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia

Targeting Mitochondrial Calcium Uptake to Eradicate Venetoclax-Resistant Acute Myeloid Leukemia Stem Cells

Age-Adapted Chemotherapy for Adults >40 Years Old with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: Single Center Outcomes

Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens

Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia

Targeting Microenvironmental Signals in Myeloid Malignancies

Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy

IL-1 Via IRAK1/4 Sustains Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse

Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic Studies

Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia

Unique Metabolic Vulnerabilities of Myelodysplastic Syndrome Stem Cells

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only